Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sarepta Surges on Rival Pfizer's DMD Gene Therapy Study Data

by Zacks Equity Research

Sarepta (SRPT) investors cheer the announcement of Pfizer's early-stage gene therapy study data, which seems to trail Sarepta's gene therapy candidate, SRP-9001's performance.

UnitedHealthcare Ties Up to Improve Eye Health of Members

by Zacks Equity Research

UnitedHealth Group's (UNH) UnitedHealthcare business collaborates with GlassesUSA.com for providing improved eye care to its eligible members.

Sanofi's Blood Disorder Candidate Gets FDA's Priority Review

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) regulatory application for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD).

MEDNAX Affiliate Ties Up With CDI to Improve Patient Care

by Zacks Equity Research

MEDNAX's (MD) affiliate Jefferson Radiology collaborates with CDI for providing enhanced healthcare services to the Springfield community.

Sweta Jaiswal, FRM headshot

Are Biotech ETFs in Trouble as Coronavirus Dims Guidance?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q1 earnings releases amid the coronavirus crisis.

Is Alexion Pharmaceuticals (ALXN) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Alexion (ALXN) Beats on Q1 Earnings & Sales, Lowers Guidance

by Zacks Equity Research

Alexion (ALXN) beats on earnings and sales in the first quarter of 2020 but lowers view due to the ongoing pandemic.

Rimmi Singhi headshot

Add Value to Your Portfolio With 5 High Earnings Yield Picks

by Rimmi Singhi

If other factors are constant while comparing stocks, the one with a higher earnings yield has the potential to provide comparatively greater returns.

Alexion Pharmaceuticals (ALXN) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Alexion (ALXN) delivered earnings and revenue surprises of 19.26% and 6.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

Kinjel Shah headshot

Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More

by Kinjel Shah

Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.

Kinjel Shah headshot

5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

by Kinjel Shah

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2020 results.

Should You Buy Alexion (ALXN) Ahead of Earnings?

by Zacks Equity Research

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) will provide pipeline updates along with financial numbers for the first quarter in its impending earnings release.

Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q1 results.

Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.

Cronos (CRON) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.

Zacks.com featured highlights include: LAUR, IMKTA, ALXN and CSIQ

by Zacks Equity Research

Zacks.com featured highlights include: LAUR, IMKTA, ALXN and CSIQ

Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.

Sumit Singh headshot

Add Value to Your Portfolio With These 4 Low P/CF Stocks

by Sumit Singh

In value investing, investors pick stocks that are cheap but fundamentally sound. So, the chance of outperformance is high when the market moves higher.

Alexion Pharmaceuticals (ALXN) Stock Moves -0.9%: What You Should Know

by Zacks Equity Research

In the latest trading session, Alexion Pharmaceuticals (ALXN) closed at $107.47, marking a -0.9% move from the previous day.

Incyte (INCY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.